ALIOS BIOPHARMA
Alios is discovering and developing novel therapeutic agents based on three platform technologies including: small molecule activators of innate immunity antiviral pathways (RNase L activation), phosphate protected nucleotide prodrug chemistry, and glycoprotein-engineering of interferons (Glycoferonâ). This complementary group of platform technologies has the potential to generate a number of distinct therapeutic products to treat a variety of serious viral infections such as chronic hepatitis B and C, HIV infection, and respiratory viruses (e.g. pandemic influenza) and emerging viral diseases (e.g. SARS).
ALIOS BIOPHARMA
Social Links:
Industry:
Biopharma Biotechnology Therapeutics
Founded:
2006-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.aliosbiopharma.com
Total Employee:
51+
Status:
Closed
Contact:
650-635-5500
Email Addresses:
[email protected]
Total Funding:
74.4 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Tag Manager Apple Mobile Web Clips Icon Google Analytics HSTS Google Maps Content Delivery Network Font Awesome
Similar Organizations
Sagimet Biosciences
Sagimet Biosciences is a biotechnology company that focuses on developing novel therapeutics to treat important diseases.
BridgeBio Pharma
BridgeBio Pharma focuses on genetic disease therapies and develops those assets with the right approach in supporting R&D.
CTI BioPharma
CTI BioPharma is a biopharmaceutical company developing oncology products for the treatment of cancer.
EnClear Therapies
EnClear Therapies is a biotechnology company developing device-based therapies for the treatment of neurodegenerative disease
Kodiak Sciences
Kodiak is designing and developing novel therapies for the treatment of retinal disease.
Milestone Pharmaceuticals
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
NGM Biopharmaceuticals
NGM Biopharmaceuticals is a drug discovery company developing biotherapeutics for the gastrointestinal endocrine system.
Numab
Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases.
Triana Biomedicines
Triana Biomedicines is a developer of a molecular glue discovery platform to regulate disease.
Zura Bio
Zura Bio is a clinical-stage biotechnology company that develops medicines for immune system disorders.
Current Advisors List
Current Employees Featured
Founder
Investors List
SR One
SR One investment in Series B - Alios BioPharma
Novartis Venture Fund
Novartis Venture Fund investment in Series B - Alios BioPharma
Roche Venture Fund
Roche Venture Fund investment in Series B - Alios BioPharma
Novo Ventures
Novo Ventures investment in Series B - Alios BioPharma
Novo Holdings
Novo Holdings investment in Venture Round - Alios BioPharma
Roche Venture Fund
Roche Venture Fund investment in Series A - Alios BioPharma
Novartis Venture Fund
Novartis Venture Fund investment in Series A - Alios BioPharma
Novo Ventures
Novo Ventures investment in Series A - Alios BioPharma
Novo Ventures
Novo Ventures investment in Series A - Alios BioPharma
Roche Venture Fund
Roche Venture Fund investment in Series A - Alios BioPharma
Official Site Inspections
http://www.aliosbiopharma.com
- Host name: aa089eb6179d1ae2b.awsglobalaccelerator.com
- IP address: 13.248.160.137
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Alios BioPharma"
Johnson & Johnson Announces Completion Of Alios Biopharma …
Nov 7, 2014 The acquisition includes Alios BioPharma’s portfolio of potential therapeutics for viral infections with the promising compound AL-8176, an orally administered antiviral therapy …See details»
Johnson & Johnson Announces Agreement To Acquire Alios …
Sep 30, 2014 This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding the acquisition of Alios BioPharma, Inc., …See details»
Alios BioPharma - PitchBook
Alios BioPharma General Information Description. Developer of novel antiviral therapies for treatment of acute and chronic infections. The company's discovery platform includes a proprietary chemical library of nucleoside analogs and …See details»
Johnson & Johnson completes acquisition of AliosBioPharma for …
Based in California, US, AliosBioPharma develops therapies for the treatment of viral diseases. The company will now be included in the infectious diseases therapeutic area of the Janssen …See details»
Johnson & Johnson completes acquisition of Alios BioPharma for …
Nov 9, 2014 Johnson & Johnson completes acquisition of Alios BioPharma for $1.75bn. US-based Johnson & Johnson (J&J) has completed the acquisition of a privately held clinical …See details»
Alios BioPharma - VentureRadar
" Alios BioPharma is a privately-held biotechnology company located in South San Francisco, CA, that is developing novel medicines aimed at the treatment of viral diseases. Alios has an …See details»
Alios BioPharma - Funding, Financials, Valuation & Investors
Alios BioPharma is a biotechnology company developing novel medicines for the treatment of viral diseases. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. ... How much …See details»
Alios BioPharma acquired by Johnson & Johnson
Johnson & Johnson have announced a definitive agreement to acquire Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for …See details»
Alios BioPharma - Contacts, Employees, Board Members
Alios BioPharma is a biotechnology company developing novel medicines for the treatment of viral diseases. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. …See details»
Johnson & Johnson buying Alios for $1.75B | AP News
Sep 30, 2014 NEW BRUNSWICK, N.J. (AP) — Johnson & Johnson is buying the biopharmaceutical company Alios BioPharma Inc. for about $1.75 billion. Menu. Menu. World. …See details»
Johnson & Johnson to acquire Alios BioPharma for $1.75bn
US-based Johnson & Johnson has signed an agreement to acquire a privately held clinical stage biopharmaceutical company, Alios BioPharma, for .75bn in cash. Based in California, US, …See details»
Alios BioPharma | EquityNet
Alios is discovering and developing novel therapeutic agents based on three platform technologies including: small molecule activators of innate immunity antiviral pathways (RNase …See details»
Alios BioPharma: From Startup To Big Pharma - Life Science Leader
Jun 1, 2016 If you had told Lawrence Blatt a decade ago that he and his team from then-fledging startup Alios BioPharma would today be working under the Big Pharma umbrella of Johnson & …See details»
Alios BioPharma - VentureRadar
Alios BioPharma is a privately-held biotechnology company located in South San Francisco, CA, that is developing novel medicines aimed at the treatment of viral diseases. Alios has an …See details»
Johnson & Johnson takes $630M hit on RSV drug bought with Alios
Oct 18, 2018 Four years ago, Johnson & Johnson splashed out $1.75 billion to take control of antiviral specialist Alios, but the lead drug from that deal now seems to be in trouble.See details»
Vertex and Alios BioPharma Announce Exclusive Worldwide …
Jun 13, 2011 Alios BioPharma is a biotechnology company located in South San Francisco, California, that is developing novel medicines aimed at the treatment of viral diseases. Alios …See details»
Alios BioPharma Raises $41 Million in Series B Financing - Yahoo …
Apr 7, 2014 Alios BioPharma, Inc., a biotechnology company developing proprietary therapeutics for respiratory viral diseases, today announced it has completed a $41 Million …See details»
J&J dumps Alios RSV drug, wiping remaining $900M off value
Mar 22, 2019 Johnson & Johnson has abandoned development of anti-RSV drug AL-8176, wiping another $900 million off the value of the assets it acquired from Alios Biopharma. The …See details»
Emerging Drug Developer: Alios BioPharma - Fierce Biotech
Alios sets sights on new, improved interferon molecule A fledgling South San Francisco biotech believes it's started down a scientific trail that could lead directly to a new and improved interferonSee details»